Peptide Atlas · Peptide

Lixisenatide

Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute coronary event, it neither raised nor lowered major cardiovascular events against placebo over a median 25 months.

established

provisional
PubChem 90472060
2 citations
0 discussions
0 followers
AVE0010
Adlyxin
Lyxumia
ZP10

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

No trial registration is cited for it. A registered trial cites as an NCT number and resolves through ClinicalTrials.gov.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.